{"id":"nct:NCT07881432","kind":"trial","title":"A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes","authors":["Eli Lilly and Company"],"author_count":1,"year":2026,"published":"2026-10-19","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07881432","source_url":"https://clinicaltrials.gov/study/NCT07881432","archive_url":"https://space-kitty.com/papers/nct:NCT07881432","updated":"2026-10-19","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity. Participation in the study will last about 2 years.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"peer_reviewed":null,"categories":["Obesity"],"details":{"acronym":"AMPLIFY-1","status":"NOT_YET_RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":2115,"sponsor":"Eli Lilly and Company","conditions":["Obesity"],"interventions":["DRUG: eloralintide and tirzepatide","DRUG: Eloralintide","DRUG: Tirzepatide","DRUG: Placebo"],"start_date":"2026-12-01","start_date_type":"ESTIMATED","primary_completion_date":"2029-10-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[{"slug":"glp1-metabolic","title":"GLP-1 & Incretin Therapies: State of the Field (October 2026)","url":"https://space-kitty.com/dossiers/glp1-metabolic"}]}